Drugs / Exl-111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07356713 | Jan → Dec 2026 expected | allergic disease | Excellergy Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-27 | Excellergy Inc. | Results Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial excellergy.com ↗
In primates, Exl-111 achieved rapid and near-complete (>99%) removal of receptor-bound IgE on basophils and induced a ~95% reduction in surface receptor (FcεRI) expression |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exl-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07356713 ↗ |
| Route | Subcutaneous | “Exl-111 is administered by subcutaneous injection in a single dose.” NCT07356713 ↗ |